XTAI
1701
Market cap201mUSD
Aug 20, Last price
21.15TWD
Name
China Chemical & Pharmaceutical Co Ltd
Chart & Performance
P/E
19.56
P/S
0.74
EPS
1.08
Div Yield, %
—
Shrs. gr., 5y
0.09%
Rev. gr., 5y
2.50%
Revenues
8.57b
+1.40%
Net income
322m
-32.51%
CFO
239m
+43.10%
Dividend
Jul 26, 20240.50003 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China Chemical & Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. The company provides sexual function supplements; cardiovascular drugs, anti-lipidemia drugs, and peripheral circulation impediment relieving agents; diabetes treatment drugs, adrenocortico steroids, and weight control drugs; and anti-infection drugs, such as antibiotics, antifungal drugs, and anti-viral drugs. It also offers nutritional supplements comprising vitamins, liver toning agents, and electrolyte and calorie preparations; antipyretic, analgesic, and anti-inflammatory medicines; digestive drugs, intestinal improvement agents, and antispasmodics; cough suppressants, antihistamines, and asthma treatment agents; BPH drugs for the urinary system; hypnotic, mental stability, and antidepressant drugs; hematology/oncology drugs; and other general preparations. In addition, the company provides over the counter drugs such as vitamins, external skin care products, cold and cough medicines, anti-inflammatory analgesics, and gastrointestinal drugs; and antibacterial and disinfection medicines. Further, it manufactures animal health products, including drugs for pigs and cattle, companion animal products, poultry drugs, and feed supplements; and offers contract manufacturing services. The company was founded in 1952 and is headquartered in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||